Chimeric immunomodulatory compounds and methods of using the same - I
First Claim
Patent Images
1. A chimeric immunomodulatory compound (CIC) comprising at least two nucleic acid moieties and at least one nonnucleic acid spacer moiety, wherein at least one nucleic acid moiety comprises the sequence 5′
- -CG-3′ and
said spacer moiety comprises HEG, TEG, propyl, butyl, hexyl, pentaerythritol, 2-(hydroxymethyl)ethyl, glycerol, 1,3-diamino-2-propanol, a polysaccharide, or a dendrimer;
and wherein said CIC has at least one immunomodulatory activity selected from the group consisting of (i) the ability to stimulate IFN-γ
production from human perpheral blood mononuclear cells and (ii) the ability to stimulate IFN-α
production from human perpheral blood mononuclear cells.
3 Assignments
0 Petitions
Accused Products
Abstract
The invention provides immunomodulatory compounds and methods for immunomodulation of individuals using the immunomodulatory compounds.
-
Citations
30 Claims
-
1. A chimeric immunomodulatory compound (CIC) comprising at least two nucleic acid moieties and at least one nonnucleic acid spacer moiety,
wherein at least one nucleic acid moiety comprises the sequence 5′ - -CG-3′ and
said spacer moiety comprises HEG, TEG, propyl, butyl, hexyl, pentaerythritol, 2-(hydroxymethyl)ethyl, glycerol, 1,3-diamino-2-propanol, a polysaccharide, or a dendrimer;
and wherein said CIC has at least one immunomodulatory activity selected from the group consisting of (i) the ability to stimulate IFN-γ
production from human perpheral blood mononuclear cells and (ii) the ability to stimulate IFN-α
production from human perpheral blood mononuclear cells. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30)
- -CG-3′ and
Specification